公开(公告)号：US20240261289A1

公开(公告)日：2024-08-08

申请号：US18562107

申请日：2022-05-17

Applicant: AMGEN INC.

Inventor： Haby HENARY ,  Gataree NGARMCHAMNANRITH ,  Joseph PARK ,  Sandeep DUTTA ,  Gregory FRIBERG ,  Brett E. HOUK ,  Omar MATHER

IPC: A61K31/519 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K45/06 ,  A61P35/00

Abstract: Provided herein are methods of treating a cancer comprising a KRAS G12C mutation in a patient with active brain metastases, comprising administering sotorasib to the patient in amount effective to treat the cancer.

公开(公告)号：US20250127782A1

公开(公告)日：2025-04-24

申请号：US18689716

申请日：2022-09-07

Applicant: AMGEN INC.

Inventor： Emily CHAN ,  Gregory FRIBERG ,  Omar Ali MATHER ,  Brett E. HOUK ,  Gataree NGARMCHAMNANRITH ,  Haby HENARY ,  Sandeep DUTTA

IPC: A61K31/519 ,  A61K31/4745 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

Abstract: Provided herein are methods of treating cancer comprising a KRAS G12C mutation in a patient comprising administering to the patient sotorasib and an anti-epidermal growth factor receptor (EGFR) antibody in amounts effective to treat the cancer. Further provided herein are methods further comprising administering FOLFIRI (irinotecan, 5-FU and leucovorin) to the patient.

公开(公告)号：US20220323446A1

公开(公告)日：2022-10-13

申请号：US17696758

申请日：2022-03-16

Applicant: Amgen Inc.

Inventor： Gregory FRIBERG ,  Haby HENARY ,  Brett E. HOUK ,  Omar A. MATHER ,  Gataree NGARMCHAMNANRITH ,  Sandeep DUTTA

IPC: A61K31/519 ,  A61K31/573 ,  A61K33/00 ,  A61K33/10 ,  A61K33/08 ,  A61K31/4439 ,  A61K31/426 ,  A61K31/341 ,  A61K31/4164 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/675 ,  A61K31/513 ,  A61K31/4166 ,  A61K31/496 ,  A61K31/435 ,  A61K31/495 ,  A61K31/536 ,  A61K31/517 ,  A61K31/439 ,  A61K31/7048 ,  A61K31/445 ,  A61K31/506 ,  A61K31/4985 ,  A61K31/58 ,  A61K31/40 ,  A61K31/522 ,  A61K31/5513 ,  A61K31/167 ,  A61K31/635 ,  A61K31/337 ,  A61P35/00 ,  A61K9/00

Abstract: Provided herein are methods of treating cancer in a patient comprising administering a total daily dose of 240 mg sotorasib to the patient, wherein the cancer is a KRAS G12C mutated cancer. Also provided herein are methods of treating KRAS G12C mutated cancer in a patient comprising administering a total daily dose of 960 mg sotorasib to the patient, and reducing the total daily dose of sotorasib to 480 mg in a patient experiencing an adverse event to the 960 mg dose of sotorasib.